NEW YORK (GenomeWeb) – Natera has filed a $200 million shelf registration, according to documents filed with the US Securities Exchange Commission.
The firm may sell from time to time, in one or more offerings, up to $200 million in securities, it said.
The molecular diagnostics company said it would use the net proceeds for continued investments in R&D for its core technology, as well as working capital and general purposes. In addition, it said it could use a portion of the proceeds to acquire complementary businesses, technologies, or other assets, although Natera said it has no agreements currently in the works for an acquisition. It may also use proceeds to repay debts or refinance.
Last week, in reporting its third quarter results, Natera said that it had $25.3 million in cash and cash equivalents and $157.7 million in short-term investments.